DENMARK - Santaris Pharma secures EUR 20.4m series-C round

Gilde Healthcare Partners has joined existing shareholders, the board of directors and management in a EUR 20.4m series-C round of funding for Santaris Pharma, a Danish pharmaceutical company. New investor Gilde contributed EUR 7.5m while the remaining EUR 12.9m was supplied by a international syndicate of investors including, BankInvest, Novo, LD, Forbion Capital Partners, Global Life Science Ventures, Sunstone Capital, Seventure, Omega, Innovation Capital and the company’s board and management. The financing round will be used to continue the development of Santaris Pharma’s pipeline of RNA medicines, and to conduct further clinical trials in 2008.